15-08-2013 дата публикации
Номер: US20130210802A1
Certain imidazopyridines (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample. 2. At least one chemical entity of claim 1 , wherein Ris chosen from phenyl claim 1 , pyridinyl claim 1 , pyrimidinyl claim 1 , pyridazinyl claim 1 , pyrazolyl claim 1 , and thiazolyl claim 1 , each of which is optionally substituted with one or more groups chosen fromhydroxy;{'sup': b', 'c', 'b', 'c, 'sub': 1', '6', '1', '4', '1', '4', '1', '4, '—NRRwherein Ris chosen from hydrogen and C-Calkyl optionally substituted with one or two groups chosen from hydroxy and —OC-Calkyl and Ris independently chosen from hydrogen and C-Calkyl optionally substituted with one or two groups chosen from hydroxy and —OC-Calkyl;'}{'sub': 3', '6', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '2', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'heterocycloalkyl optionally substituted with one or two groups chosen from hydroxy, C-Ccycloalkyl, C-Calkyl, —C-Calkyl-OH, —C-Calkyl-O—C-Calkyl, —C-Calkyl-NH, —N(C-Calkyl)(C-Calkyl), —NH(C-Calkyl), —C(O)(C-Calkyl), —C(O)(C-Calkyl-OH), and —OC-Calkyl;'}{'sub': 1', '6', '3', '6', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '2', '1', '4', '1', '4', '1', '4', '1', '4, '—OC-Calkyl optionally substituted with one or two groups chosen from hydroxy, C-Ccycloalkyl, C-Calkyl, —C-Calkyl-OH, —C-Calkyl-O—C-Calkyl, —C-Calkyl-NH, —N(C-Calkyl)(C-Calkyl), —NH(C-Calkyl), and —OC-Calkyl; and'}{'sub': 1', '6', '3', '6', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '2', '1', '4', '1', '4', '1', '4', '1', '4, 'C-Calkyl optionally substituted with one or two groups chosen from ...
Подробнее
